Anti-dll4 antibodies and methods using same
AssigneeGenentech, Inc.
InventorsMinhong Yan, Yan Wu
Life of this patent
Estimating the term…
Abstract
The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies.
Claims43
An isolated anti-DLL4 antibody comprising:
- (a) at least one, two, three, four or five hypervariable region (HVR) sequences selected from the group consisting of:
- (i) HVR-L1 comprising sequence A1-A11, wherein A1-A11 is RASQDVSTAVA (SEQ ID NO:10)
- (ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is SASFLYS (SEQ ID NO:11)
- (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSYTGTVT (SEQ ID NO:18)
- (iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GFTFTDNWIS (SEQ ID NO:1);
- (v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GYISPNSGFTYYADSVKG (SEQ ID NO:8) and
- (vi) HVR-H3 comprising sequence F1-F15, wherein F1-F15 is VYYCARDNFGGYFDY (SEQ ID NO:9);
- and
- (b) at least one variant HVR, wherein the variant HVR sequence comprises modification of at least one residue of the sequence depicted in SEQ ID NOs:1-18.
An isolated anti-DLL4 antibody comprising:
- (a) at least one, two, three, four or five hypervariable region (HVR) sequences selected from the group consisting of:
- (i) HVR-L1 comprising sequence A1-A11, wherein A1-A11 is RASQDVSTAVA (SEQ ID NO:10)
- (ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is SASFLYS (SEQ ID NO:11)
- (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSYNGPST (SEQ ID NO:15)
- (iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GFTFTDNWIS (SEQ ID NO:1)
- (v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GVINPNSGATEYADSVKG (SEQ ID NO:5) and
- (vi) HVR-H3 comprising sequence F1-F15, wherein F1-F15 is VYYCARDNFGGYFDY (SEQ ID NO:9);
- and
- (b) at least one variant HVR, wherein the variant HVR sequence comprises modification of at least one residue of the sequence depicted in SEQ ID NOs:1-18.
An isolated anti-DLL4 antibody comprising one, two, three, four, five or six HVRs, wherein each HVR comprises, consists or consists essentially of a sequence selected from the group consisting of SEQ ID NOs:
- 1-18, and wherein SEQ ID NO:10 corresponds to an HVR-L1, SEQ ID NO:11 corresponds to an HVR-L2, SEQ ID NO:12, 13, 14, 15, 16, 17, or 18 correspond to an HVR-L3, SEQ ID NO:1 or 2 correspond to an HVR-H1, SEQ ID NO:3, 4, 5, 6, 7 or 8 correspond to an HVR-H2, and SEQ ID NO:9 corresponds to an HVR-H3.
A method for detection of DLL4, the method comprising detecting DLL4-anti-DLL4 antibody complex in a biological sample.
A method for diagnosing a disorder associated with DLL4 expression, the method comprising detecting DLL4-anti-DLL4 antibody complex in a biological sample from a patient having or suspected of having the disorder.
Dependencies are inferred from the claim text.